BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2183 related articles for article (PubMed ID: 15726515)

  • 1. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
    Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study.
    Chougule PB; Akhtar MS; Akerley W; Ready N; Safran H; McRae R; Nigri P; Bellino J; Koness J; Radie-Keane K; Wanebo H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):58-63. PubMed ID: 10210541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV).
    Wanebo HJ; Chougule P; Ready N; Koness RJ; Akerley W; McRae R; Nigri P; Leone L; Webber B; Safran H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):77-84. PubMed ID: 10210544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Lippman SM; Ginsberg L; Diaz E; Papadimitrakopoulou V; Feng L; Francisco M; Garden A; Kies MS; Myers J; Clayman G; Hong WK
    Cancer; 2002 Jul; 95(2):322-30. PubMed ID: 12124833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer.
    Aisner J; Belani CP; Kearns C; Conley B; Hiponia D; Engstrom C; Zuhowski E; Egorin MJ
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):17-21. PubMed ID: 7481856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm.
    Arnold SM; Regine WF; Ahmed MM; Valentino J; Spring P; Kudrimoti M; Kenady D; Desimone P; Mohiuddin M
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1411-7. PubMed ID: 15050317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of combined radiation, paclitaxel and carboplatin for locally advanced non-small cell lung carcinoma.
    Nguyen NP; Leonardo JM; Karlsson U; Vos P; Bullock L; Thomas P; Lepera P; Ludin A; Chu C; Salehpour M; Jendrasiak G; Sallah S
    Anticancer Res; 2002; 22(6B):3429-35. PubMed ID: 12552935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
    Haraf DJ; Rosen FR; Stenson K; Argiris A; Mittal BB; Witt ME; Brockstein BE; List MA; Portugal L; Pelzer H; Weichselbaum RR; Vokes EE
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5936-43. PubMed ID: 14676118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial.
    Socinski MA; Clark JA; Halle J; Steagall A; Kaluzny B; Rosenman JG
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-117-S12-122. PubMed ID: 9331135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot trial of paclitaxel, carboplatin, and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck.
    Conley B; Jacobs M; Suntharalingam M; Zacharski D; Ord RA; Gray W; Aisner J
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-78-S2-80. PubMed ID: 9045343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
    Czito BG; Cohen DP; Kelsey CR; Lockhart AC; Bendell JC; Willett CG; Petros WP; D'Amico TA; Truax R; Hurwitz HI
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1066-72. PubMed ID: 17881149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999.
    Dunphy FR; Dunleavy TL; Harrison BR; Trinkaus KM; Kim HJ; Stack BC; Needles B; Boyd JH
    Cancer; 2001 Mar; 91(5):940-8. PubMed ID: 11251945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules.
    Moreno-Jiménez M; Valero J; López-Picazo JM; Arbea L; Aristu J; Cambeiro M; Alcalde J; Martínez-Monge R
    Am J Clin Oncol; 2010 Apr; 33(2):137-43. PubMed ID: 19786847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
    Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
    Amrein PC; Clark JR; Supko JG; Fabian RL; Wang CC; Colevas AD; Posner MR; Deschler DG; Rocco JW; Finkelstein DM; McIntyre JF
    Cancer; 2005 Oct; 104(7):1418-27. PubMed ID: 16116597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 110.